期刊
NATURE REVIEWS DRUG DISCOVERY
卷 18, 期 7, 页码 527-551出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/s41573-019-0019-2
关键词
-
资金
- Canadian Institutes of Health Research [201709FDN-CEBA-116200]
- Diabetes Canada [DI-5-17-5302-GS]
- Medical Research Council UK [MC-A654-5QB10]
- Canada Research Chair
- J. Bruce Duncan Chair in Metabolic Diseases
- MRC [MC_U120027537] Funding Source: UKRI
Since the discovery of AMP-activated protein kinase (AMPK) as a central regulator of energy homeostasis, many exciting insights into its structure, regulation and physiological roles have been revealed. While exercise, caloric restriction, metformin and many natural products increase AMPK activity and exert a multitude of health benefits, developing direct activators of AMPK to elicit beneficial effects has been challenging. However, in recent years, direct AMPK activators have been identified and tested in preclinical models, and a small number have entered clinical trials. Despite these advances, which disease(s) represent the best indications for therapeutic AMPK activation and the long-term safety of such approaches remain to be established.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据